NL300364I2 - Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie - Google Patents

Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Info

Publication number
NL300364I2
NL300364I2 NL300364C NL300364C NL300364I2 NL 300364 I2 NL300364 I2 NL 300364I2 NL 300364 C NL300364 C NL 300364C NL 300364 C NL300364 C NL 300364C NL 300364 I2 NL300364 I2 NL 300364I2
Authority
NL
Netherlands
Prior art keywords
pandemic
influenza
influenza strain
california
strain
Prior art date
Application number
NL300364C
Other languages
English (en)
Other versions
NL300364I1 (nl
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300364(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NL300364I1 publication Critical patent/NL300364I1/nl
Publication of NL300364I2 publication Critical patent/NL300364I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NL300364C 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie NL300364I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (en) 1999-04-06 2000-04-05 Recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
NL300364I1 NL300364I1 (nl) 2009-01-05
NL300364I2 true NL300364I2 (nl) 2017-08-03

Family

ID=26826080

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300365C NL300365I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een influenzastam die verondersteld wordt nauwe gelijkenis te vertonen met een influenzastam die verantwoordelijk zal zijn voor een pandemieNIBRG-14
NL300364C NL300364I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL300365C NL300365I2 (nl) 1999-04-06 2008-11-13 Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een influenzastam die verondersteld wordt nauwe gelijkenis te vertonen met een influenzastam die verantwoordelijk zal zijn voor een pandemieNIBRG-14

Country Status (19)

Country Link
EP (4) EP2910629B1 (nl)
JP (3) JP5543048B2 (nl)
KR (1) KR100702275B1 (nl)
CN (2) CN101851636B (nl)
AT (2) ATE368729T1 (nl)
AU (1) AU4073300A (nl)
BR (1) BRPI0009580B8 (nl)
CA (2) CA2928263A1 (nl)
CY (2) CY1108520T1 (nl)
DE (6) DE60035778T2 (nl)
DK (3) DK2345716T3 (nl)
ES (3) ES2533622T3 (nl)
FR (1) FR11C0027I2 (nl)
HK (2) HK1148778A1 (nl)
IL (2) IL145702A0 (nl)
MX (1) MXPA01010082A (nl)
NL (2) NL300365I2 (nl)
PT (2) PT1185615E (nl)
WO (1) WO2000060050A2 (nl)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
KR100702275B1 (ko) * 1999-04-06 2007-03-30 위스콘신 얼럼나이 리서어치 화운데이션 백신 및 유전자 치료용 재조합 인플루엔자 바이러스
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
ATE353370T1 (de) * 1999-07-14 2007-02-15 Sinai School Medicine In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
UA84254C2 (ru) 2000-04-28 2008-10-10 Ст. Джуд Чилдренз Ресерч Хоспитал МИНИМАЛЬНАЯ ПЛАЗМИДНАЯ СИСТЕМА ДЛЯ ГЕНЕРИРОВАНИЯ ИНФЕКЦИОННЫХ МИНУС-ЦЕПОЧЕЧНЫХ РНК ВИРУСОВ С КЛОНИРОВАННОЙ ВИРУСНОЙ кДНК, КЛЕТКА-ХОЗЯИН, КОТОРАЯ ВКЛЮЧАЕТ ПЛАЗМИДНУЮ СИСТЕМУ, СПОСОБ ПРОДУЦИРОВАНИЯ ИНФЕКЦИОННОГО МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА И СПОСОБ ПРИВИВКИ СУБЪЕКТА ОТ ИНФЕКЦИИ МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА
BRPI0111830B8 (pt) * 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
EP1862550A1 (en) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
HUE050222T2 (hu) * 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CA2482946C (en) 2002-04-26 2013-09-17 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
AU2004249133B2 (en) * 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CA2568015C (en) 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
EP1824990B1 (en) 2004-12-08 2015-02-18 MedImmune, LLC Methods of producing influenza vaccine compositions
EP2295542B1 (en) 2004-12-24 2013-01-30 Abbott Biologicals B.V. Rescue of influenza virus
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP1951301A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
PL1945252T3 (pl) * 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
HUE037464T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
WO2007146057A2 (en) * 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CA2659267C (en) 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2523587T3 (es) 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
WO2010006144A2 (en) 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
JP5343079B2 (ja) 2008-08-18 2013-11-13 北里第一三共ワクチン株式会社 トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
RU2535970C2 (ru) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2013529913A (ja) 2010-06-02 2013-07-25 アヴィール グリーン ヒルズ バイオテクノロジー リサーチ ディベロプメント トレード アクチエンゲゼルシャフト Ｒｎａウィルスの作製のための方法及びヘルパーウィルス
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US20140302077A1 (en) 2011-09-02 2014-10-09 Westfaelische Wilhelms-Universitaet Munester Live attenuated influenza virus
JP2014532620A (ja) 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
WO2017040203A1 (en) * 2015-08-28 2017-03-09 Yoshihiro Kawaoka Generation of infectious influenza viruses from virus-like particles
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
CA3074202A1 (en) * 2017-08-28 2019-03-07 Wisconsin Alumni Research Foundation Nanocapsules for delivering ribonucleoproteins
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
AU3760495A (en) * 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
EP0704533A1 (en) * 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (en) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
KR100702275B1 (ko) * 1999-04-06 2007-03-30 위스콘신 얼럼나이 리서어치 화운데이션 백신 및 유전자 치료용 재조합 인플루엔자 바이러스

Also Published As

Publication number Publication date
NL300364I1 (nl) 2009-01-05
BR0009580A (pt) 2002-01-02
IL145702A0 (en) 2002-07-25
DE122008000061I1 (de) 2009-02-12
ATE368729T1 (de) 2007-08-15
IL145702A (en) 2010-04-15
DK2345716T3 (en) 2015-02-09
CY1112140T1 (el) 2015-11-04
EP1185615A2 (en) 2002-03-13
JP6224645B2 (ja) 2017-11-01
EP2345716A1 (en) 2011-07-20
DE122008000035I1 (de) 2009-05-20
AU4073300A (en) 2000-10-23
EP1820853A2 (en) 2007-08-22
ES2290024T3 (es) 2008-02-16
EP1820853A3 (en) 2007-10-03
CN1350578A (zh) 2002-05-22
DE122008000058I1 (de) 2009-05-07
EP2910629A1 (en) 2015-08-26
JP2011182797A (ja) 2011-09-22
PT1820853E (pt) 2012-01-03
FR11C0027I2 (fr) 2021-12-31
JP5543048B2 (ja) 2014-07-09
CA2928263A1 (en) 2000-10-12
EP2910629B1 (en) 2018-09-19
ATE525461T1 (de) 2011-10-15
JP2003528570A (ja) 2003-09-30
EP1185615B1 (en) 2007-08-01
HK1148778A1 (zh) 2011-09-16
CN1350578B (zh) 2010-05-12
ES2373405T3 (es) 2012-02-03
PT1185615E (pt) 2007-10-04
NL300365I1 (nl) 2009-01-05
JP2015119735A (ja) 2015-07-02
EP1820853B1 (en) 2011-09-21
WO2000060050A2 (en) 2000-10-12
FR11C0027I1 (fr) 2011-08-26
NL300365I2 (nl) 2017-08-03
CA2365526C (en) 2016-07-05
BR0009580B1 (pt) 2014-11-25
EP2345716B1 (en) 2015-01-14
CN101851636B (zh) 2015-11-25
BRPI0009580B8 (pt) 2021-05-25
HK1214298A1 (zh) 2016-07-22
KR20010113044A (ko) 2001-12-24
JP5775351B2 (ja) 2015-09-09
DE122008000014I1 (de) 2011-12-01
DK1185615T3 (da) 2007-11-05
KR100702275B1 (ko) 2007-03-30
DE122011100037I1 (de) 2012-03-22
WO2000060050A3 (en) 2001-01-18
DE60035778D1 (de) 2007-09-13
CA2365526A1 (en) 2000-10-12
DE60035778T2 (de) 2008-04-30
MXPA01010082A (es) 2002-04-24
ES2533622T3 (es) 2015-04-13
CN101851636A (zh) 2010-10-06
DK1820853T3 (da) 2011-12-19
CY1108520T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
NL300364I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
NL300368I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/Indonesia/05/2005 (H5N1) (PR8-IBCDC-RG2), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
BR0214750A (pt) Imidazoquinolinas tioéter substituìdas
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
CO5540349A2 (es) Preparacion vacunal de virus de influenza inactivado
DE60214157D1 (de) Desinfizierende und solubilisierende steroidzusammensetzungen
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
NO20015502L (no) Sulfonamid- og sulfamidsubstituerte imidazokinoliner
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
EP2078083A4 (en) NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR
ATE359279T1 (de) Moschus-geruchsstoffe
AU2001238401A1 (en) Cold-adapted equine influenza viruses
BR0312522A (pt) Método para a preparação de trombina inativada por vìrus, trombina, formulação farmacêutica, e, kit farmacêutico
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
NO20014841L (no) Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet
BR0308660A (pt) C-17 espirolactonização e 6,7 oxidação de esteróides
ATE213646T1 (de) Grippe-impfstoff
UY28435A1 (es) Mezclas de oligosacáridos derivados de la heparina, su preparación y las composiciones farmacéuticas que las contienen
HUP0300727A2 (hu) Nukleinsav-konstrukciók, ezekkel transzformált vaszkuláris sejtek, ezeket a konstrukciókat hasznosító gyógyászati kompozíciók, és eljárások angiogenezis indukálásához
ATE377020T1 (de) Kristallines gamma-lacton der17beta-hydroxy-
SI1696940T1 (sl) Univerzalno uporabna virusno inaktivirana krvna plazma, proizvedena iz delov plazme ne-kavkazijca
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
GT200100093A (es) Pirazoles sustituidos como inhibidores de cinasa p38